|
|
|
|
World Courier
|
|
Customising the Cold Chain
|
|
Of all the statistics emerging around the global pharmaceutical industry
this year, two big numbers capture the attention of both manufacturers
and their logistics partners: $248 billion, the amount the “BRIC”
nations (Brazil, Russia, India and China) are poised to account for in
pharmaceutical sales for by 2016; and $8 billion, the amount global
pharma will spend on cold chain logistics in 2014. Why are these two
numbers so noteworthy? They demonstrate that as R&D goes, so goes
logistics. As products evolve to meet demands for more targeted
therapies, demand for more targeted logistics solutions grows as well.
And that means a need for customization for everything from clinical
trial samples to finished product.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Merck to Provide Provantage® End-to-End Development and Manufacturing Services to Y-mAbs for Lead Antibody Compound
More info >> |
|
 |
White Papers |
 |
|
Pharmacovigilance and Risk Management Information in Centralised Applications in the EU
United BioSource Corporation (UBC)
Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >> |
|
 |
Industry Events |
 |
BioProcess International Conference & Exhibition (BPI)
25-28 September 2017, Hynes Convention Center, Boston, Massachusetts, USA
BioProcess International
Conference & Exhibition (BPI) is
the largest bioprocessing event bringing you the science, technologies and
partners needed to accelerate promising biologics towards commercial
success.
More info >> |
|
|
|
